title: [Terazosin in the treatment of benign prostatic hypertrophy].
abstract: Benign prostatic hypertrophy provokes clinical manifestations correlated on one hand to a static obstructive component, due to the increase in glandular size, and on the other hand to a dynamic component, controlled by the alpha adrenergic autonomic system which gives the smooth muscular tonus of the prostatic adenoma. The alpha adrenergic receptor block reduces the dynamic component, improves the clinical and urodynamic parameters determined by the infra-bladder obstruction in patients with BPH. The selective alpha 1, long acting antagonists especially, such as terazosin, offer a safe and efficient therapy for selected patients suffering from BPH. They also have the indisputable benefit of mono-administration. In this study the basic concepts of BPH treatment with terazosin are discussed.
authors.affiliation: Clinica Urologica II, Università degli Studi di Milano, Polo di Monza.
authors.forename: M
authors.initials: M
authors.lastname: Andres
authors.forename: O
authors.initials: O
authors.lastname: De Cobelli
authors.forename: L
authors.initials: L
authors.lastname: Carmignani
authors.forename: R
authors.initials: R
authors.lastname: Musci
authors.forename: E
authors.initials: E
authors.lastname: Kocjancic
authors.forename: M
authors.initials: M
authors.lastname: Panizzutti
authors.forename: F
authors.initials: F
authors.lastname: Rocco
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin